OBJECTIVE: To report a case of a microprolactinoma in a male-to-female transsexual treated with estrogens and cyproterone acetate. DESIGN: Case report. SETTING: Endocrinology unit in a university hospital. PATIENT(S): A 33-year-old male-to-female transsexual with prolactin level of 10 ng/mL. INTERVENTION(S): Treatment with equine-conjugated estrogens (2.5 mg/day, orally) and cyproterone acetate (100 mg/day, orally) during 6 months. MAIN OUTCOME MEASURE(S): Her levels of prolactin were repeatedly found to be elevated to a maximum of 133 ng/mL, and magnetic resonance imaging (MRI) revealed a pituitary mass of 5x4x4 mm. RESULT(S): Discontinuation of the cross-sex hormone treatment did not reduce the levels of prolactin. The use of dopaminergic-agonist therapy normalized them and reduced the size of the microadenoma. After sex-reassignment surgery, she was treated with low-dose estradiol transdermal patches and presented normal levels of prolactin and appropriate levels of 17beta-estradiol and testosterone with a stable image in MRI. CONCLUSION(S): We report a case of prolactinoma after treatment with equine-conjugated estrogens and cyproterone acetate. We recommend long-term follow-up observation consisting of a periodic evaluation of prolactin levels and any symptoms suggestive of hyperprolactinemia to detect as early as possible complications derived from cross-sex hormone therapy. Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
OBJECTIVE: To report a case of a microprolactinoma in a male-to-female transsexual treated with estrogens and cyproterone acetate. DESIGN: Case report. SETTING: Endocrinology unit in a university hospital. PATIENT(S): A 33-year-old male-to-female transsexual with prolactin level of 10 ng/mL. INTERVENTION(S): Treatment with equine-conjugated estrogens (2.5 mg/day, orally) and cyproterone acetate (100 mg/day, orally) during 6 months. MAIN OUTCOME MEASURE(S): Her levels of prolactin were repeatedly found to be elevated to a maximum of 133 ng/mL, and magnetic resonance imaging (MRI) revealed a pituitary mass of 5x4x4 mm. RESULT(S): Discontinuation of the cross-sex hormone treatment did not reduce the levels of prolactin. The use of dopaminergic-agonist therapy normalized them and reduced the size of the microadenoma. After sex-reassignment surgery, she was treated with low-dose estradiol transdermal patches and presented normal levels of prolactin and appropriate levels of 17beta-estradiol and testosterone with a stable image in MRI. CONCLUSION(S): We report a case of prolactinoma after treatment with equine-conjugated estrogens and cyproterone acetate. We recommend long-term follow-up observation consisting of a periodic evaluation of prolactin levels and any symptoms suggestive of hyperprolactinemia to detect as early as possible complications derived from cross-sex hormone therapy. Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Authors: Lisa M Wilson; Kellan E Baker; Ritu Sharma; Vadim Dukhanin; Kristen McArthur; Karen A Robinson Journal: Int J Transgend Health Date: 2020-09-17
Authors: Kirsten L Dennison; Aaron C Chack; Maureen Peters Hickman; Quincy Eckert Harenda; James D Shull Journal: PLoS One Date: 2018-09-27 Impact factor: 3.240